Xian Lijian M.D., M.M.S, Professor, Doctorial supervisor
Telephone: 86-20-87765368-7335
Fax: 86-20-87754506
E-mail: LJ_XIAN@YAHOO.COM

Background:
    Dr. Xian Lijian graduated in 1966 from Sun Yat-sen University of Medical Sciences (six years system). She received the Degree of Medical Master in 1982 from the same school. Since that time she has been working in Cancer Institute, Sun Yat-sen university of Medical Sciences(SUMS). Dr. Xian received the position of Professor in 1997. As a visiting scholar, She worked in Institute of Medical Chemistry and Biochemistry, University of Innsbruck, Austria in 1994 and then in Laboratory of Rhythms and Chrono-chemotherapy, Institute of Cancer and Immunology, Paris. France, in 2000.
    The field of investigation is the pharmacology of anti-tumor drugs. The focus is the screen, detoxification and increase effect of anti-tumor drugs as well as the study on action mechanism of anti-tumor drugs. More than 40 papers were published.
    The research on detoxification of adriamycin directing by Dr.Xian indicated that Vitamin B12 reduced the toxicity of Adriamycin without interfering with the anti-tumor effect of adriamycin. The pre-clinical Pharmacological study indicated that the reducing of cardiotoxicity caused by Adriamycin, the increasing of survival time, and significant improving of quality of life in dogs which were administrated Adriamycin combining with Vitamin B12. The research on the mechanism of action demonstrated Vitamin B12 could scavenge the free radicals caused by Adriamycin directly in vitro. In vivo, Vitamin B12 can protect myocardium from the toxicity of Adriamycin by the action of interfering with the metabolism of free radicals caused by Adriamycin. In tumor cells, the ability for using added Vitamin B12 was very limited comparing with normal cells. Therefore, it is possible to use Vitamin B12 for the rescue of normal cells without affecting the antitumor activity of Adriamycin. It suggested that Vitamin B12 could be used as an anti-radical drug. The series of study received the prize on progressive science and technique (the second class) awarded by National Education Ministry in 1997.
    In these years, study focuses on the screen of new anti-tumor drugs, which target in the nuclear enzymes, related to DNA synthesis. Dr. Xian took part in the study on “ The relationship of DNA TopoisomeraseⅡwith anti-tumor drugs”, then directed the research on “ The relationship of DNA polymerase with anti-tumor drugs” and “ The research on reversing the multi-drug resistance of tumor cells caused by altered Topoisomerase Ⅱ(AT-MDR)”. All of those studies were supported by National Natural Science Foundation of China. A new screening method for anti-tumor drugs, which targeted in DNA polymerase, was established as a complement of present screening methods. It was reported that mitoxantrone is a strong inhibitor of DNA Polymerase a ,b , and g , the inhibitory mode is competition with respect to template DNA. Some plant growth regulators--extract of camellia sinesis and extract of camellia ptilophylla chang as well as berberine were reported as DNA Polymerase inhibitors. Their anti-tumor activities were proved. The study on reversing multi-drug resistance had found some effective reversing drugs to AT-MDR and elucidated the mechanism of action. The works are well on.
    Recently, the research on the circadian rhythms and chrono-chemotherapy of nasopharyngeal carcinoma was conducted. “211 Principal Discipline Project” and “France—China collaboration Foundation for advanced Science and Technique” supported the work. A long tern stable collaboration between the Laboratory of rhythms and chrono-chemotherpy, Institute of Cancer & Immunology, Paris with Cancer Institute of SUMS was established.
    The Basic Research and Clinical Use of Chrono-Chemotherapy of Cancer was supported by Principal Discipline Foundation of National Health Ministry in 2001. At the same time, the research on developing new antitumor drugs from PP2A inhibitor was initiated and supported by Principal Foundation of Guangdong Province Natural Science Fund.
    Dr. Xian is director of Department of Research on Practical Technology, associate director of Biotherapy Center, editor of journals such as Chinese Journal of Cancer and Guangzhou Medicine Journal, expert of " National Agency of Drug Supervision", expert of " Guangdong Agency of Drug Supervision"," National Education Ministry", " National Science and Technology Ministry" and National Natural Science Foundation Specialist.
 
MAIN PUBLICATIONS :
1. Xian LJ, Li HX, Liu ZC et al: Effect of mitoxantrone on DNA polymerase of Ehrlich ascites carcinoma cells. ACTA PHARMACOLOGICA SINICA 1998,19(4): 356-358
2 Sun J, Xian LJ, Cao QY, et al. Circadian rhythms of DNA synthesis in human nasopharyngeal carcinoma cells transplanted in nude mice. Chinese Journal of Cancer 2001, 20(2): 128-130
3. Xian LJ, Liu ZC, Pan QC et al: The inhibitory effect of extract of camellia sinensis and extract of camellia ptilophylla chang on DNA polymerase of Ehrlich ascites carcinoma cells. Chinese journal of cancer research 1998, 10(4): 251-255
4. Xian LJ, Liang YN, Zhang QW et al: The effect of berberine and some plant drugs on DNA polymerase and growth of tumor cells. Tumor 2000,20(1): 1-3.
5. Xian LJ, Liu ZC, Liang YJ et al: A study on the inhibitory action of several plant growth regulations derivatives on DNA polymerase and tumor growth. Chinese Journal of Cancer 1997,16(3): 168-171
6. Xian LJ, Pan QC et al: The regulator of Protein Kinase C and a new promising drug—Bryostatin. Chinese Journal of Cancer 1996, 6 (1):59-61
7. Xian LJ, Pan WG, and Luo SH et al: The dynamic observation of free radical levels of mouse myocardium after administration of single-dose and multi-dose Adriamycin and the interfering action of Vitamin B12. Chinese Journal of Oncology 1995, 17(S): 87-92
8. Xian LJ, Liu ZC, Xie BF et al: A preliminary study on the inhibitory effect of maleic anhydride copolymers on the activity of Topoisomerase Ⅱ. Chinese Journal of Cancer 1991,10(4): 271-274